Assessing the Detectability of Cannabinoid Analogs (Delta-8 THC, Delta-10 THC and CBD) and their Major Metabolites in Six Commercial Cannabinoid Urine Screening Kits

• NCJ Number: 308105
• Author(s): Ashley A. Pokhai
• Date Published: 2022
• Length: 39 pages
• Grant Number(s): 15PNIJ-21-GG-04188-RESS
• Agencies: NIJ-Sponsored
• Publication Type: Report (Study/Research)

Annotation

This study assessed detectability of cannabinoid analogs in six urine screening kits.

Abstract

To evaluate the ability of six commercially available homogeneous urine cannabinoid screening kits to detect ∆8-THC, CBD and their major metabolites, and ∆10-THC chiral analogs at 50 ng/mL and 20 or 25 ng/mL cutoff concentrations. Six urine immunoassay kits (Abbott Cannabinoids – Abbott Diagnostics, LZI Cannabinoids (cTHC) Enzyme Immunoassay – Lin-Zhi International, DRI® Cannabinoid Assay and CEDIA™ THC – Thermo Fisher Scientific, ONLINE DAT Cannabinoid II – Roche Diagnostics, and Syva EMIT®II Plus – Siemens Healthineers) were evaluated at two different cutoff concentrations: 50 ng/mL and 20 or 25 ng/mL. The six commercially available homogeneous urine cannabinoid screening kits were able to detect ∆8-THC, 11-OH-∆8-THC, 11-COOH-∆8-THC, 6-OH-CBD, 7-OH-CBD, all ∆10-THC chiral analogs, and olivetol with varying selectivity depending on the screening kit. The kits were not able to detect CBD, 7-COOH-CBD, Abn-CBD, CBDA-A, and olivetolic acid. The analysis was performed on an Abbott Architect Plus c4000 (Abbott Diagnostics). ∆8-THC, CBD, olivetol and their major metabolites, and ∆10-THC chiral analogs were evaluated. (Published Abstract Provided)